These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8195829)

  • 1. Structure-activity relationships of dihydrofolate reductase inhibitors.
    Bowden K; Harris NV; Watson CA
    J Chemother; 1993 Dec; 5(6):377-88. PubMed ID: 8195829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.
    Wyss PC; Gerber P; Hartman PG; Hubschwerlen C; Locher H; Marty HP; Stahl M
    J Med Chem; 2003 Jun; 46(12):2304-12. PubMed ID: 12773035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basis of selectivity of antibacterial diaminopyrimidines.
    Baccanari DP; Kuyper LF
    J Chemother; 1993 Dec; 5(6):393-9. PubMed ID: 8195830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
    Kuyper LF; Baccanari DP; Jones ML; Hunter RN; Tansik RL; Joyner SS; Boytos CM; Rudolph SK; Knick V; Wilson HR; Caddell JM; Friedman HS; Comley JC; Stables JN
    J Med Chem; 1996 Feb; 39(4):892-903. PubMed ID: 8632413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
    Gangjee A; Elzein E; Queener SF; McGuire JJ
    J Med Chem; 1998 Apr; 41(9):1409-16. PubMed ID: 9554874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative correlation between molar refractivity and the inhibition of dihydrofolate reductase by 2,4-diamino-5-benzylpyrimidines.
    Kumar NA; Rao MN
    Indian J Biochem Biophys; 1986 Feb; 23(1):58-60. PubMed ID: 3525396
    [No Abstract]   [Full Text] [Related]  

  • 8. Nonlinear quantitative structure-activity relationship for the inhibition of dihydrofolate reductase by pyrimidines.
    Hirst JD
    J Med Chem; 1996 Aug; 39(18):3526-32. PubMed ID: 8784450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
    Gangjee A; Lin X; Queener SF
    J Med Chem; 2004 Jul; 47(14):3689-92. PubMed ID: 15214795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of anticancer drugs: computer graphic analysis of dihydrofolate reductase inhibitors.
    Cody V
    Prog Clin Biol Res; 1985; 172B():275-84. PubMed ID: 3991714
    [No Abstract]   [Full Text] [Related]  

  • 12. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation of the selectivity of the dihydrofolate reductase inhibitor 5-substituted benzyl-2,4-diamino-pyrimidines].
    Li RL; Fang ZX
    Yao Xue Xue Bao; 1986 Oct; 21(10):753-60. PubMed ID: 3577775
    [No Abstract]   [Full Text] [Related]  

  • 14. Quinazolines as inhibitors of dihydrofolate reductase. 1.
    Ashton WT; Walker FC; Hynes JB
    J Med Chem; 1973 Jun; 16(6):694-7. PubMed ID: 4715004
    [No Abstract]   [Full Text] [Related]  

  • 15. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of neural network QSPR models for Hansch substituent constants. 2. Applications in QSAR studies of HIV-1 reverse transcriptase and dihydrofolate reductase inhibitors.
    Chiu TL; So SS
    J Chem Inf Comput Sci; 2004; 44(1):154-60. PubMed ID: 14741022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
    Peppard WJ; Schuenke CD
    Curr Opin Investig Drugs; 2008 Feb; 9(2):210-25. PubMed ID: 18246524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.
    Oefner C; Bandera M; Haldimann A; Laue H; Schulz H; Mukhija S; Parisi S; Weiss L; Lociuro S; Dale GE
    J Antimicrob Chemother; 2009 Apr; 63(4):687-98. PubMed ID: 19211577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational analysis of dihydrofolate reductase inhibitors: use of computer graphics in drug design.
    Cody V; Sutton PA; Welsh WJ
    Proc West Pharmacol Soc; 1986; 29():151-3. PubMed ID: 3763602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.